The Week

SNDL gained 8.73% this week, closing at $1.37, while the S&P 500 slid 1.43% — a relative outperformance of around 10 percentage points. The session started quietly on Monday (17 Aug) at $1.25, dipping to an intraweek low of $1.23 before momentum picked up from Wednesday. By Friday (21 Aug), the stock hit a high of $1.40 before settling at $1.37. No major catalysts drove the move; the rebound appears to be a function of sector rotation and light positioning rather than a headline-driven rally.

Analyst Ratings

Two brokers cover SNDL: one rates it buy and the other overweight, with no hold, underweight or sell ratings. The consensus recommendation is buy, and the consensus target sits at $3.495, implying an upside of about 155% from the latest price. The single target estimate — both the high and low end of the range are $3.495 — signals a uniform view among the covering analysts. Within the pharmaceuticals industry group of 201 names, SNDL ranks 150th by analyst rating.

The Week Ahead

Tuesday (25 Aug) brings a busy macro calendar for the US, including FHFA and Case Shiller home-price indices, consumer confidence and new-home sales data. These prints will offer fresh clues on the health of the consumer and housing sectors. SNDL itself has no earnings or events on the schedule, so the stock is likely to take its cue from broader sector sentiment and macro flows in the coming week.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.